Search Result

Results for "

Lipase MAGL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MAGL (18) Autophagy (1) Calcium Channel (1) Cannabinoid Receptor (1) FAAH (4) Histamine Receptor (1) Phospholipase (1)
By Research Areas:	Cancer (3) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (11)

Inhibitors & Agonists

Recombinant Proteins

Antibodies

Targets Recommended: MAGL Lipase ATGL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

HY-119283

MAGL-IN-5 1 Publications Verification CAY10499	MAGL FAAH	Metabolic Disease
MAGL-IN-5 (CAY10499) is a non-selective lipase inhibitor with IC₅₀ values of 144, 90, and 14 nM for human recombinant monoacylglycerol lipase(MAGL),hormone sensitive lipase(HSL), and fatty acid amide hydrolase(FAAH) respectively .

HY-108613

JJKK 048

1 Publications Verification

MAGL Neurological Disease

JJKK 048 is an ultrapotent and highly selective inhibitor of Monoacylglycerol lipase (MAGL).

JJKK 048 1 Publications Verification	MAGL	Neurological Disease
JJKK 048 is an ultrapotent and highly selective inhibitor of Monoacylglycerol lipase (MAGL).

HY-116143

MAGL-IN-12	MAGL	Metabolic Disease
SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC₅₀s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .

HY-157038

MAGL-IN-8

MAGL Inflammation/Immunology

MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ of 2.5 ± 0.4 nM for hMAGL .

MAGL-IN-8	MAGL	Inflammation/Immunology
MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ of 2.5 ± 0.4 nM for hMAGL .

HY-157041

MAGL-IN-10	MAGL	Cancer
MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .

HY-12332

JW 642 1 Publications Verification	MAGL	Neurological Disease
JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.

HY-146342

FAAH/MAGL-IN-3	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC₅₀ values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-136562

N-Arachidonyl maleimide

MAGL Metabolic Disease

N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC₅₀ value of 140 nM .

N-Arachidonyl maleimide	MAGL	Metabolic Disease
N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC₅₀ value of 140 nM .

HY-117632

Elcubragistat 1 Publications Verification ABX-1431	MAGL	Neurological Disease
Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 14 nM.

HY-163202

MAGL-IN-13	MAGL Calcium Channel	Neurological Disease Cancer
MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for MAGL,with IC₅₀ values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .

HY-15250

JZL195 4 Publications Verification	FAAH MAGL Autophagy	Neurological Disease
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 2 and 4 nM, respectively .

HY-118158

FAAH/MAGL-IN-4	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

HY-133130

JNJ-42226314	MAGL	Neurological Disease
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .

HY-117474

MJN110 2 Publications Verification	MAGL	Neurological Disease
MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .

HY-116141

7-Hydroxycoumarinyl arachidonate 7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate	Phospholipase MAGL	Others
7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .

HY-120851

O-7460	Cannabinoid Receptor	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .

HY-111538

MAGL-IN-1	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

HY-121422

JZP-361	MAGL Histamine Receptor	Inflammation/Immunology
JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC₅₀ of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .

HY-150702

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

Species:	Human (2) Rat (1)
Tag:	His (2) Tag Free (1)
Source:	P. pastoris (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701985

	MGLL Protein, Human (His) MGLL; Monoglyceride Lipase; MGL; HU-K5; LysophosphoLipase homolog; LysophosphoLipase-like; Monoacylglycerol Lipase; MAGL	Human	E. coli
	MGLL proteins convert monoacylglycerides into free fatty acids and glycerol. MGLL Protein, Human (His) is the recombinant human-derived MGLL protein, expressed by E. coli , with N-6*His labeled tag. The total length of MGLL Protein, Human (His) is 302 a.a., .

HY-P71755

	Monoglyceride lipase Protein, Rat (P.pastoris, His) Mgll; Mgl2; Monoglyceride Lipase; MGL; Monoacylglycerol Lipase; MAGL	Rat	P. pastoris
	Monoglyceride lipase is a key enzyme in lipid metabolism and plays a key role in converting monoacylglycerols into free fatty acids and glycerol, contributing to important cellular processes. In addition to being involved in lipid metabolism, this enzyme also hydrolyzes the endocannabinoid 2-arachidonoylglycerol, thereby affecting the complex regulation of endocannabinoid signaling, nociception, and pain perception. Monoglyceride lipase Protein, Rat (P.pastoris, His) is the recombinant rat-derived Monoglyceride lipase protein, expressed by P. pastoris , with N-His labeled tag. The total length of Monoglyceride lipase Protein, Rat (P.pastoris, His) is 303 a.a., with molecular weight of ~35.5 kDa.

HY-P701984

	MGLL Protein, Human MGLL; Monoglyceride Lipase; MGL; HU-K5; LysophosphoLipase homolog; LysophosphoLipase-like; Monoacylglycerol Lipase; MAGL	Human	E. coli
	MGLL proteins convert monoacylglycerides into free fatty acids and glycerol. MGLL Protein, Human is the recombinant human-derived MGLL protein, expressed by E. coli , with tag free. The total length of MGLL Protein, Human is 302 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.